ID   APOE_RAT                Reviewed;         312 AA.
AC   P02650;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   02-OCT-2024, entry version 186.
DE   RecName: Full=Apolipoprotein E;
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=Apoe;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3797247; DOI=10.1093/nar/14.23.9527;
RA   Fukazawa C., Matsumoto A., Taylor L.M.;
RT   "Complete nucleotide sequence of the gene encoding the rat apolipoprotein
RT   E.";
RL   Nucleic Acids Res. 14:9527-9528(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3020048; DOI=10.1016/s0021-9258(18)67087-5;
RA   Fung W.-P., Howlett G.J., Schreiber G.;
RT   "Structure and expression of the rat apolipoprotein E gene.";
RL   J. Biol. Chem. 261:13777-13783(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6190813; DOI=10.1016/s0021-9258(18)32155-0;
RA   McLean J.W., Fukazawa C., Taylor J.M.;
RT   "Rat apolipoprotein E mRNA. Cloning and sequencing of double-stranded
RT   cDNA.";
RL   J. Biol. Chem. 258:8993-9000(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=7766086; DOI=10.1007/bf00191183;
RA   Nomura N., Yamada H., Matsubara N., Horinouchi S., Beppu T.;
RT   "Secretion by Saccharomyces cerevisiae of rat apolipoprotein E as a fusion
RT   to Mucor rennin.";
RL   Appl. Microbiol. Biotechnol. 42:865-870(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 87-100; 114-122; 130-144; 191-199; 202-216; 226-236 AND
RP   262-270, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus;
RA   Lubec G., Chen W.-Q.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: APOE is an apolipoprotein, a protein associating with lipid
CC       particles, that mainly functions in lipoprotein-mediated lipid
CC       transport between organs via the plasma and interstitial fluids. APOE
CC       is a core component of plasma lipoproteins and is involved in their
CC       production, conversion and clearance. Apolipoproteins are amphipathic
CC       molecules that interact both with lipids of the lipoprotein particle
CC       core and the aqueous environment of the plasma. As such, APOE
CC       associates with chylomicrons, chylomicron remnants, very low density
CC       lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but
CC       shows a preferential binding to high-density lipoproteins (HDL). It
CC       also binds a wide range of cellular receptors including the LDL
CC       receptor/LDLR and the very low-density lipoprotein receptor/VLDLR that
CC       mediate the cellular uptake of the APOE-containing lipoprotein
CC       particles. Finally, APOE has also a heparin-binding activity and binds
CC       heparan-sulfate proteoglycans on the surface of cells, a property that
CC       supports the capture and the receptor-mediated uptake of APOE-
CC       containing lipoproteins by cells. {ECO:0000250|UniProtKB:P02649}.
CC   -!- SUBUNIT: Homotetramer. May interact with ABCA1; functionally associated
CC       with ABCA1 in the biogenesis of HDLs. May interact with APP/A4 amyloid-
CC       beta peptide; the interaction is extremely stable in vitro but its
CC       physiological significance is unclear. May interact with MAPT. May
CC       interact with MAP2. In the cerebrospinal fluid, interacts with secreted
CC       SORL1. Interacts with PMEL; this allows the loading of PMEL luminal
CC       fragment on ILVs to induce fibril nucleation.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02649}.
CC       Secreted, extracellular space {ECO:0000250|UniProtKB:P02649}. Secreted,
CC       extracellular space, extracellular matrix
CC       {ECO:0000250|UniProtKB:P02649}. Extracellular vesicle
CC       {ECO:0000250|UniProtKB:P02649}. Endosome, multivesicular body
CC       {ECO:0000250|UniProtKB:P02649}. Note=In the plasma, APOE is associated
CC       with chylomicrons, chylomicrons remnants, VLDL, LDL and HDL
CC       lipoproteins. Lipid poor oligomeric APOE is associated with the
CC       extracellular matrix in a calcium- and heparan-sulfate proteoglycans-
CC       dependent manner. Lipidation induces the release from the extracellular
CC       matrix. Colocalizes with CD63 and PMEL at exosomes and in intraluminal
CC       vesicles within multivesicular endosomes.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: APOE exists as multiple glycosylated and sialylated glycoforms
CC       within cells and in plasma. The extent of glycosylation and sialylation
CC       are tissue and context specific. {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: Glycated in plasma VLDL. {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- MISCELLANEOUS: The mature protein has no cysteine residues; however, in
CC       different allelic variants where cysteine residues replace arginine at
CC       positions 155 or 168, binding of Apo-E to cell membrane receptors is
CC       decreased. The amino end of this protein is therefore thought to
CC       interact with the receptor.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04979; CAA28650.1; -; Genomic_DNA.
DR   EMBL; J02582; AAA40755.1; -; Genomic_DNA.
DR   EMBL; S76779; AAC60703.1; -; mRNA.
DR   EMBL; BC086581; AAH86581.1; -; mRNA.
DR   PIR; A26189; LPRTE.
DR   RefSeq; NP_001257610.1; NM_001270681.1.
DR   RefSeq; NP_001257611.1; NM_001270682.1.
DR   RefSeq; NP_001257612.1; NM_001270683.1.
DR   RefSeq; NP_001257613.1; NM_001270684.1.
DR   RefSeq; NP_620183.2; NM_138828.3.
DR   AlphaFoldDB; P02650; -.
DR   SMR; P02650; -.
DR   BioGRID; 247757; 3.
DR   IntAct; P02650; 4.
DR   STRING; 10116.ENSRNOP00000071702; -.
DR   iPTMnet; P02650; -.
DR   PhosphoSitePlus; P02650; -.
DR   PaxDb; 10116-ENSRNOP00000050968; -.
DR   GeneID; 25728; -.
DR   KEGG; rno:25728; -.
DR   UCSC; RGD:2138; rat.
DR   AGR; RGD:2138; -.
DR   CTD; 348; -.
DR   RGD; 2138; Apoe.
DR   VEuPathDB; HostDB:ENSRNOG00000018454; -.
DR   eggNOG; ENOG502QVD6; Eukaryota.
DR   InParanoid; P02650; -.
DR   OrthoDB; 4591103at2759; -.
DR   PhylomeDB; P02650; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-RNO-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-RNO-8963888; Chylomicron assembly.
DR   Reactome; R-RNO-8963901; Chylomicron remodeling.
DR   Reactome; R-RNO-8964026; Chylomicron clearance.
DR   Reactome; R-RNO-8964058; HDL remodeling.
DR   Reactome; R-RNO-975634; Retinoid metabolism and transport.
DR   PRO; PR:P02650; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000018454; Expressed in liver and 19 other cell types or tissues.
DR   ExpressionAtlas; P02650; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0042627; C:chylomicron; IDA:RGD.
DR   GO; GO:0034360; C:chylomicron remnant; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0034365; C:discoidal high-density lipoprotein particle; IDA:RGD.
DR   GO; GO:0005769; C:early endosome; IDA:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005768; C:endosome; IDA:RGD.
DR   GO; GO:0070062; C:extracellular exosome; ISS:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:1903561; C:extracellular vesicle; IBA:GO_Central.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IDA:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:RGD.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0005770; C:late endosome; IDA:RGD.
DR   GO; GO:1990777; C:lipoprotein particle; ISO:RGD.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0042470; C:melanosome; ISO:RGD.
DR   GO; GO:0005874; C:microtubule; IDA:RGD.
DR   GO; GO:0097487; C:multivesicular body, internal vesicle; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005635; C:nuclear envelope; IDA:RGD.
DR   GO; GO:0043083; C:synaptic cleft; ISO:RGD.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:ARUK-UCL.
DR   GO; GO:0001540; F:amyloid-beta binding; IDA:RGD.
DR   GO; GO:0016209; F:antioxidant activity; ISO:RGD.
DR   GO; GO:0120020; F:cholesterol transfer activity; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0046848; F:hydroxyapatite binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISS:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; ISO:RGD.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:RGD.
DR   GO; GO:0071813; F:lipoprotein particle binding; ISO:RGD.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISS:UniProtKB.
DR   GO; GO:0046911; F:metal chelating activity; ISO:RGD.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; ISO:RGD.
DR   GO; GO:0005543; F:phospholipid binding; IDA:RGD.
DR   GO; GO:0046983; F:protein dimerization activity; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; ISO:RGD.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; ISO:RGD.
DR   GO; GO:0055090; P:acylglycerol homeostasis; IBA:GO_Central.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; ISO:RGD.
DR   GO; GO:0042982; P:amyloid precursor protein metabolic process; ISO:RGD.
DR   GO; GO:0048844; P:artery morphogenesis; ISO:RGD.
DR   GO; GO:0071397; P:cellular response to cholesterol; IEP:RGD.
DR   GO; GO:0071361; P:cellular response to ethanol; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0006707; P:cholesterol catabolic process; ISO:RGD.
DR   GO; GO:0033344; P:cholesterol efflux; ISS:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISO:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0034382; P:chylomicron remnant clearance; ISS:UniProtKB.
DR   GO; GO:0072359; P:circulatory system development; ISO:RGD.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISO:RGD.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISO:RGD.
DR   GO; GO:0010467; P:gene expression; ISO:RGD.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; ISS:UniProtKB.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; ISO:RGD.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISO:RGD.
DR   GO; GO:0071831; P:intermediate-density lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0055088; P:lipid homeostasis; ISO:RGD.
DR   GO; GO:0006629; P:lipid metabolic process; ISO:RGD.
DR   GO; GO:0006869; P:lipid transport; IDA:RGD.
DR   GO; GO:0010877; P:lipid transport involved in lipid storage; ISO:RGD.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0042159; P:lipoprotein catabolic process; ISO:RGD.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IDA:RGD.
DR   GO; GO:0035641; P:locomotory exploration behavior; ISO:RGD.
DR   GO; GO:0015909; P:long-chain fatty acid transport; ISO:RGD.
DR   GO; GO:0007616; P:long-term memory; ISO:RGD.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; ISO:RGD.
DR   GO; GO:0051651; P:maintenance of location in cell; ISO:RGD.
DR   GO; GO:0032438; P:melanosome organization; ISS:UniProtKB.
DR   GO; GO:1905907; P:negative regulation of amyloid fibril formation; ISS:UniProtKB.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; ISO:RGD.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; ISO:RGD.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; ISO:RGD.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IDA:RGD.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; ISO:RGD.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:RGD.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISO:RGD.
DR   GO; GO:0010544; P:negative regulation of platelet activation; ISO:RGD.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; ISO:RGD.
DR   GO; GO:0050709; P:negative regulation of protein secretion; ISO:RGD.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; ISO:RGD.
DR   GO; GO:0090209; P:negative regulation of triglyceride metabolic process; ISO:RGD.
DR   GO; GO:0031175; P:neuron projection development; ISO:RGD.
DR   GO; GO:0031102; P:neuron projection regeneration; TAS:RGD.
DR   GO; GO:0038060; P:nitric oxide-cGMP-mediated signaling; ISO:RGD.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; ISO:RGD.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEP:RGD.
DR   GO; GO:0014012; P:peripheral nervous system axon regeneration; IEP:RGD.
DR   GO; GO:0033700; P:phospholipid efflux; ISO:RGD.
DR   GO; GO:0044794; P:positive regulation by host of viral process; ISO:RGD.
DR   GO; GO:1900223; P:positive regulation of amyloid-beta clearance; ISS:UniProtKB.
DR   GO; GO:0045773; P:positive regulation of axon extension; IDA:RGD.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISO:RGD.
DR   GO; GO:0090205; P:positive regulation of cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; ISO:RGD.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0045807; P:positive regulation of endocytosis; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISO:RGD.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood-brain barrier; ISO:RGD.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; ISO:RGD.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; ISO:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISO:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; ISO:RGD.
DR   GO; GO:0017038; P:protein import; ISO:RGD.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISO:RGD.
DR   GO; GO:1905906; P:regulation of amyloid fibril formation; ISO:RGD.
DR   GO; GO:1902991; P:regulation of amyloid precursor protein catabolic process; ISO:RGD.
DR   GO; GO:1900221; P:regulation of amyloid-beta clearance; ISO:RGD.
DR   GO; GO:0042981; P:regulation of apoptotic process; ISO:RGD.
DR   GO; GO:2000822; P:regulation of behavioral fear response; ISO:RGD.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; ISO:RGD.
DR   GO; GO:1905890; P:regulation of cellular response to very-low-density lipoprotein particle stimulus; ISO:RGD.
DR   GO; GO:0090181; P:regulation of cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0045088; P:regulation of innate immune response; ISO:RGD.
DR   GO; GO:0097006; P:regulation of plasma lipoprotein particle levels; ISO:RGD.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; ISO:RGD.
DR   GO; GO:0051246; P:regulation of protein metabolic process; ISO:RGD.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; ISO:RGD.
DR   GO; GO:0050807; P:regulation of synapse organization; ISO:RGD.
DR   GO; GO:0090207; P:regulation of triglyceride metabolic process; IDA:RGD.
DR   GO; GO:0061771; P:response to caloric restriction; ISO:RGD.
DR   GO; GO:1904421; P:response to D-galactosamine; IEP:RGD.
DR   GO; GO:0002021; P:response to dietary excess; ISO:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; ISO:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0010043; P:response to zinc ion; IEP:RGD.
DR   GO; GO:0043691; P:reverse cholesterol transport; ISO:RGD.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISO:RGD.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISO:RGD.
DR   GO; GO:0071830; P:triglyceride-rich lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0042311; P:vasodilation; ISO:RGD.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; ISO:RGD.
DR   GO; GO:0019068; P:virion assembly; ISO:RGD.
DR   Gene3D; 1.20.120.20; Apolipoprotein; 2.
DR   InterPro; IPR000074; ApoA_E.
DR   InterPro; IPR050163; Apolipoprotein_A1/A4/E.
DR   PANTHER; PTHR18976; APOLIPOPROTEIN; 1.
DR   PANTHER; PTHR18976:SF2; APOLIPOPROTEIN E; 1.
DR   Pfam; PF01442; Apolipoprotein; 1.
DR   SUPFAM; SSF58113; Apolipoprotein A-I; 1.
PE   1: Evidence at protein level;
KW   Chylomicron; Direct protein sequencing; Endosome; Extracellular matrix;
KW   Glycoprotein; HDL; Heparin-binding; Lipid transport; Lipid-binding;
KW   Oxidation; Phosphoprotein; Reference proteome; Repeat; Secreted; Signal;
KW   Transport; VLDL.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..312
FT                   /note="Apolipoprotein E"
FT                   /id="PRO_0000001996"
FT   REPEAT          72..93
FT                   /note="1"
FT   REPEAT          94..115
FT                   /note="2"
FT   REPEAT          116..137
FT                   /note="3"
FT   REPEAT          138..159
FT                   /note="4"
FT   REPEAT          160..181
FT                   /note="5"
FT   REPEAT          182..203
FT                   /note="6"
FT   REPEAT          204..225
FT                   /note="7"
FT   REPEAT          226..247
FT                   /note="8"
FT   REGION          72..247
FT                   /note="8 X 22 AA approximate tandem repeats"
FT   REGION          150..160
FT                   /note="LDL and other lipoprotein receptors binding"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          150..160
FT                   /note="LDL receptor binding"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          202..282
FT                   /note="Lipid-binding and lipoprotein association"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          258..312
FT                   /note="Homooligomerization"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          270..282
FT                   /note="Specificity for association with VLDL"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   BINDING         154..157
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   BINDING         221..228
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   MOD_RES         135
FT                   /note="Methionine sulfoxide"
FT                   /evidence="ECO:0000250|UniProtKB:P08226"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CONFLICT        104
FT                   /note="A -> T (in Ref. 1; CAA28650)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        110
FT                   /note="A -> T (in Ref. 3; no nucleotide entry and 4;
FT                   AAC60703)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="E -> D (in Ref. 3; no nucleotide entry and 4;
FT                   AAC60703)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        206..213
FT                   /note="GAGAAQPL -> RWRRPAP (in Ref. 1; CAA28650 and 3; no
FT                   nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        309..310
FT                   /note="LE -> WR (in Ref. 3; no nucleotide entry and 4;
FT                   AAC60703)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   312 AA;  35753 MW;  8180EEE933378D92 CRC64;
     MKALWALLLV PLLTGCLAEG ELEVTDQLPG QSDQPWEQAL NRFWDYLRWV QTLSDQVQEE
     LQSSQVTQEL TVLMEDTMTE VKAYKKELEE QLGPVAEETR ARLAKEVQAA QARLGADMED
     LRNRLGQYRN EVNTMLGQST EELRSRLSTH LRKMRKRLMR DADDLQKRLA VYKAGAQEGA
     ERGVSAIRER LGPLVEQGRQ RTANLGAGAA QPLRDRAQAL SDRIRGRLEE VGNQARDRLE
     EVREQMEEVR SKMEEQTQQI RLQAEIFQAR IKGWFEPLVE DMQRQWANLM EKIQASVATN
     SIASTTVPLE NQ
//
